Cagrilintide
An investigational amylin analogue studied alone and combined with semaglutide as CagriSema. Phase 2 complete; phase 3 REDEFINE programme reporting.
Metabolic & Weight
Eloralintide
An investigational selective amylin analogue in phase 2 obesity trials. Early data has been reported at conferences; peer-reviewed publication is limited.
Overview
Amylin is a hormone released with insulin after meals that tells the brain the meal is finished. Eloralintide is a long-acting synthetic version designed to hit amylin receptors selectively rather than also stimulating the closely related calcitonin receptor. The idea is to get the appetite effect with fewer of the side effects that come from broader receptor activity, and to do it with a weekly injection.
A long-acting peptide agonist selective for the AMY receptor complexes (calcitonin receptor heterodimerised with RAMP1-3) over the calcitonin receptor alone. Amylin receptor activation in the area postrema and nucleus tractus solitarius reduces meal size and reinforces GLP-1 and leptin signalling; selectivity is the differentiating claim relative to cagrilintide, which retains substantial calcitonin receptor activity. Phase 1 and phase 2 dose-ranging in obesity have been conducted, with weight reduction reported over 12 weeks.
Research areas
ObesityAppetite regulationAmylin biology
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Weekly subcutaneous dosing across escalating cohorts over 12 weeks in phase 2Full protocol details are not yet in the peer-reviewed record. | Phase 2 obesity dose-ranging programme |
Trial status
Phase 2 in obesity, with phase 1 completed. Results to date reported primarily through conference presentations and company disclosures.
Reported safety signals
- Nausea and vomiting are the expected class effects for amylin receptor agonists.
- No long-term safety data exists — the longest reported exposure is measured in months.
- Anything sold as "eloralintide" outside a trial is not the investigational product and has no verified identity.
Common questions
How is this different from cagrilintide?
Cagrilintide activates both amylin and calcitonin receptors. Eloralintide is designed to be selective for the amylin receptor complexes. Whether that selectivity translates into a better tolerability profile in people is exactly what the phase 2 programme is testing, and it has not been answered yet.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →